Penwest

Penwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. Penwest is currently developing A0001, or alpha tocopherol quinone, a coenzyme Q10 analog demonstrated in-vitro to improve mitochondrial respiratory chain diseases. Penwest is also applying its drug delivery technologies and drug formulation expertise to the formulation of our collaborators' product candidates under licensing collaborations.

Penwest Clinical Trial information for Friedreich’s Ataxia and MELAS:

The Friedreich's Ataxia Research Alliance (FARA) is a non-profit organization dedicated to curing Friedreich’s Ataxia (FA) through research. FARA grants and programs provide support for basic and translational FA research, pharmaceutical/ biotech drug development, clinical trials, and scientific conferences. FARA also serves as a catalyst, between the public and scientific community, to create worldwide exchanges of information that drive medical advances. For individuals with FA, FARA hosts the largest international patient registry that notifies patients of clinical trials and other ways to participate in research.

For more information about the Friedreich’s Ataxia (FA) clinical trial please click on the links below:

www.curefa.org or clinicaltrials.gov

For information concerning the MELAS clinical trial, please click on the link below:

clinicaltrials.gov

RECENT PRESS RELEASES

August 9, 2010
Penwest Pharmaceuticals Agrees to be Acquired by Endo Pharmaceuticals for $5.00 per Share in Cash

August 4, 2010
Penwest Reports Record Revenue and Earnings for Second Quarter of 2010

DRUG DELIVERY TECHNOLOGIES

Click here to learn about
licensing our technologies

UPCOMING EVENTS

August 12-13, 2010
Bank of America Specialty pharma Conference, South Hampton, NY

September 15-17, 2010
Thomas Weisel Healthcare Conference, Boston, MA

PRODUCT PIPELINE